Results

1–8 of 8 results for pharmacokinetic

Safety, Tolerability, and Properties of Novel C3 Inhibitor BI-C in Patients With Geographic Atrophy
Brian B. Berger, MD
Annual Meeting Talks
2025
Population Pharmacokinetics and Safety of OPT-302 an Anti-VEGF-C--D Trap in Patients With Retinal Vascular Diseases
Dante Joseph Pieramici, MD
Annual Meeting Talks
2023
12-Month Ocular Pharmacokinetic Study of EYP-1901 a Sustained-Release Intravitreal Formulation of the Tyrosine Kinase Inhibitor Vorolanib
Rishi P. Singh, MD
Annual Meeting Talks
2023
Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Annual Meeting Talks
2023
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Archway Trial
John W. Kitchens, MD
Annual Meeting Talks
2021
Clinical Evaluation and PK/PD Modeling of the DARPin Therapeutic Abicipar for the Treatment of Neovascular Age‐Related Macular Degeneration
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2020
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab: From PRN Refills in Phase 2 Ladder to Fixed 24-Week Refills In Phase 3 Archway
Dilsher S. Dhoot, MD
Annual Meeting Talks
2020
Pharmacokinetic Profile of the Port Delivery System with Ranibizumab (PDS) in the Phase 3 Archway Trial
Peter A. Campochiaro, MD
Updates from the Field
2021